Breast Cancer Research and Treatment

, Volume 99, Issue 3, pp 313–321

Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women

Authors

    • Department of Medicine and the Herbert Irving Comprehensive Cancer CenterCollege of Physicians and Surgeons Columbia University
    • Department of EpidemiologyMailman School of Public Health, Columbia University
    • New York Presbyterian Hospital
  • Xiaoyan Wang
    • Department of EpidemiologyMailman School of Public Health, Columbia University
  • Russell McBride
    • Department of EpidemiologyMailman School of Public Health, Columbia University
  • Judith S. Jacobson
    • Department of EpidemiologyMailman School of Public Health, Columbia University
  • Victor R. Grann
    • Department of Medicine and the Herbert Irving Comprehensive Cancer CenterCollege of Physicians and Surgeons Columbia University
    • Department of EpidemiologyMailman School of Public Health, Columbia University
    • New York Presbyterian Hospital
  • Alfred I. Neugut
    • Department of Medicine and the Herbert Irving Comprehensive Cancer CenterCollege of Physicians and Surgeons Columbia University
    • Department of EpidemiologyMailman School of Public Health, Columbia University
    • New York Presbyterian Hospital
Epidemiology

DOI: 10.1007/s10549-006-9206-z

Cite this article as:
Hershman, D.L., Wang, X., McBride, R. et al. Breast Cancer Res Treat (2006) 99: 313. doi:10.1007/s10549-006-9206-z

Summary

Background

Delay in the diagnosis of breast cancer is associated with worse stage distribution at diagnosis and decreased survival. However, the occurrence of delay in the delivery of adjuvant therapy and its impact on prognosis is not well understood.

Methods

To investigate the timeliness of initiation of adjuvant chemotherapy following surgery for breast cancer, we used data from the Surveillance, Epidemiology, and End-Results (SEER)–Medicare database. Among women ≥ 65 years diagnosed between 1992 and 1999 with stages I–II breast cancer, we used linear regression and Cox proportional hazards models to investigate the time intervals between surgery and initiation of adjuvant chemotherapy, factors associated with delay, and the effect of delay on survival.

Results

Our sample consisted of 5003 women who received adjuvant chemotherapy. Of these, 47% initiated chemotherapy within 1 month, 37% between 1 and 2 months, 6% between 2 and 3 months and 10% >3 months (delay) following surgery. Delay was associated with increasing age, residing in a rural location, being unmarried, earlier tumor stage, hormone receptor positivity, mastectomy, and non-receipt of radiation therapy. Survival did not differ among patients who initiated chemotherapy within 1, 2, or 3 months after surgery. Delay beyond 3 months was, however, associated with increased disease-specific mortality (HR 1.69; 95% CI 1.31–2.19) and overall mortality (HR 1.46; 95% CI 1.21–1.75).

Conclusions

Among older patients, moderate delays in the receipt of adjuvant chemotherapy occur frequently, but long delays (>3 months) are uncommon. While early initiation of therapy is no benefit, significant delays are associated with increased mortality. Whether this reflects the medical impact of the delay of chemotherapy or factors associated with delay is unclear, but until this is clarified, patients should be encouraged to initiate treatment without significant delay.

Keywords

breast cancerchemotherapydelayelderlySEER–Medicare

Copyright information

© Springer Science+Business Media, Inc. 2006